Literature DB >> 33404385

COVID-19 in children: Pathogenesis and current status.

Lawrence D Frenkel1, Fernando Gomez2, Joseph A Bellanti3.   

Abstract

Background: Since its initial description in December 2019 in Wuhan, China, coronavirus disease 2019 (COVID-19) has rapidly progressed into a worldwide pandemic, which has affected millions of lives. Unlike the disease in adults, the vast majority of children with COVID-19 have mild symptoms and are largely spared from severe respiratory disease. However, there are children who have significant respiratory disease, and some may develop a hyperinflammatory response similar to that seen in adults with COVID-19 and in children with Kawasaki disease (KD), which has been termed multisystem inflammatory syndrome in children (MIS-C). Objective: The purpose of this report was to examine the current evidence that supports the etiopathogenesis of COVID-19 in children and the relationship of COVID-19 with KD and MIS-C as a basis for a better understanding of the clinical course, diagnosis, and management of these clinically perplexing conditions.
Results: The pathogenesis of COVID-19 is carried out in two distinct but overlapping phases of COVID-19: the first triggered by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) itself and the second by the host immune response. Children with KD have fewer of the previously described COVID-19-associated KD features with less prominent acute respiratory distress syndrome and shock than children with MIS-C.
Conclusion: COVID-19 in adults usually includes severe respiratory symptoms and pathology, with a high mortality. It has become apparent that children are infected as easily as adults but are more often asymptomatic and have milder disease because of their immature immune systems. Although children are largely spared from severe respiratory disease, they can present with a SARS-CoV-2-associated MIS-C similar to KD.

Entities:  

Year:  2021        PMID: 33404385     DOI: 10.2500/aap.2021.42.200104

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  12 in total

1.  Eosinophilic esophagitis: from discovery to effective treatment.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-05-01       Impact factor: 2.873

2.  The allergist and IgE: The realization that allergic diseases are not all IgE mediated.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-05-01       Impact factor: 2.587

3.  SARS-CoV-2 infection and the human immune system: A continuing journey of discovery.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-11-01       Impact factor: 2.587

4.  The global burden of vaccine-preventable infectious diseases in children less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?

Authors:  Lawrence D Frenkel
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

5.  Vaccine preventable diseases, vaccine hesitancy, and COVID-19: A role for the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

Review 6.  COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines.

Authors:  Giuseppina Malcangi; Alessio Danilo Inchingolo; Angelo Michele Inchingolo; Fabio Piras; Vito Settanni; Grazia Garofoli; Giulia Palmieri; Sabino Ceci; Assunta Patano; Antonio Mancini; Luigi Vimercati; Damiano Nemore; Arnaldo Scardapane; Biagio Rapone; Alexandra Semjonova; Maria Teresa D'Oria; Luigi Macchia; Ioana Roxana Bordea; Giovanni Migliore; Antonio Scarano; Felice Lorusso; Gianluca Martino Tartaglia; Delia Giovanniello; Ludovica Nucci; Nicola Maggialetti; Antonio Parisi; Marina Di Domenico; Nicola Brienza; Silvio Tafuri; Pasquale Stefanizzi; Luigi Curatoli; Alberto Corriero; Maria Contaldo; Francesco Inchingolo; Gianna Dipalma
Journal:  Children (Basel)       Date:  2022-02-12

7.  Clinical features and severe acute respiratory syndrome-coronavirus-2 structural protein-based serology of Mexican children and adolescents with coronavirus disease 2019.

Authors:  Karen Cortés-Sarabia; Armando Cruz-Rangel; Alejandro Flores-Alanis; Marcela Salazar-García; Samuel Jiménez-García; Griselda Rodríguez-Martínez; Juan Pablo Reyes-Grajeda; Rosa Isela Rodríguez-Téllez; Genaro Patiño-López; Israel Parra-Ortega; Oscar Del Moral-Hernández; Berenice Illades-Aguiar; Miguel Klünder-Klünder; Horacio Márquez-González; Adrián Chávez-López; Victor M Luna-Pineda
Journal:  PLoS One       Date:  2022-08-15       Impact factor: 3.752

8.  Multisystem inflammatory syndrome in children (MIS-C) showing disseminated aspergillosis, cytomegalovirus reactivation and persistent SARS-COV-2: Case report with autopsy review.

Authors:  Mana Taweevisit; Ariya Chindamporn; Kritsaporn Sujjavorakul; Rujipat Samransamruajkit; Paul Scott Thorner
Journal:  Pathol Res Pract       Date:  2022-09-05       Impact factor: 3.309

Review 9.  Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.

Authors:  Mehran Ghasemzadeh; Alireza Ghasemzadeh; Ehteramolsadat Hosseini
Journal:  Hum Immunol       Date:  2021-09-08       Impact factor: 2.850

Review 10.  Therapeutic Strategies for COVID-19 Lung Disease in Children.

Authors:  Elisabetta Gatti; Marta Piotto; Mara Lelii; Mariacarola Pensabene; Barbara Madini; Lucia Cerrato; Vittoria Hassan; Stefano Aliberti; Samantha Bosis; Paola Marchisio; Maria Francesca Patria
Journal:  Front Pediatr       Date:  2022-03-07       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.